» Authors » David J Shields

David J Shields

Explore the profile of David J Shields including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 1481
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Orris B, Sung M, Bhat S, Xu Y, Huynh K, Han S, et al.
Nucleic Acids Res . 2023 Nov; 51(22):12443-12458. PMID: 37930833
The dNTPase activity of tetrameric SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 (SAMHD1) plays a critical role in cellular dNTP regulation. SAMHD1 also associates with stalled DNA replication...
2.
Orris B, Sung M, Bhat S, Xu Y, Huynh K, Han S, et al.
bioRxiv . 2023 Jul; PMID: 37398126
The dNTPase activity of tetrameric SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 (SAMHD1) plays a critical role in cellular dNTP regulation. SAMHD1 also associates with stalled DNA replication...
3.
Hidalgo M, Garcia-Carbonero R, Lim K, Messersmith W, Garrido-Laguna I, Borazanci E, et al.
Cancer Res Commun . 2023 Mar; 2(11):1326-1333. PMID: 36970055
Purpose: To assess the preclinical efficacy, clinical safety and efficacy, and MTD of palbociclib plus nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma (PDAC). Experimental Design: Preclinical activity was tested...
4.
Orris B, Huynh K, Ammirati M, Han S, Bolanos B, Carmody J, et al.
Nucleic Acids Res . 2022 Jul; 50(13):7545-7559. PMID: 35801923
SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 (SAMHD1) is driven into its activated tetramer form by binding of GTP activator and dNTP activators/substrates. In addition, the inactive monomeric...
5.
Schubert N, Chen C, Rodriguez A, Koster J, Dowless M, Pfister S, et al.
Eur J Cancer . 2022 Jun; 170:196-208. PMID: 35671543
Background: Childhood cancer is still a leading cause of death around the world. To improve outcomes, there is an urgent need for tailored treatment. The systematic evaluation of existing preclinical...
6.
Vassal G, Houghton P, Pfister S, Smith M, Caron H, Li X, et al.
Mol Cancer Ther . 2021 Jun; 20(8):1462-1468. PMID: 34108262
Cancer remains the leading cause of disease-related death in children. For the many children who experience relapses of their malignant solid tumors, usually after very intensive first-line therapy, curative treatment...
7.
Salvador-Barbero B, Alvarez-Fernandez M, Zapatero-Solana E, El Bakkali A, Menendez M, Lopez-Casas P, et al.
Cancer Cell . 2020 Oct; 38(4):584. PMID: 33049208
No abstract available.
8.
Molina-Sanchez P, Ruiz de Galarreta M, Yao M, Lindblad K, Bresnahan E, Bitterman E, et al.
Gastroenterology . 2020 Aug; 159(6):2203-2220.e14. PMID: 32814112
Background And Aims: The pattern of genetic alterations in cancer driver genes in patients with hepatocellular carcinoma (HCC) is highly diverse, which partially explains the low efficacy of available therapies....
9.
Salvador-Barbero B, Alvarez-Fernandez M, Zapatero-Solana E, El Bakkali A, Menendez M, Lopez-Casas P, et al.
Cancer Cell . 2020 Feb; 37(3):340-353.e6. PMID: 32109375
Inhibition of the cell-cycle kinases CDK4 and CDK6 is now part of the standard treatment in advanced breast cancer. CDK4/6 inhibitors, however, are not expected to cooperate with DNA-damaging or...
10.
Munoz-Espin D, Rovira M, Galiana I, Gimenez C, Lozano-Torres B, Paez-Ribes M, et al.
EMBO Mol Med . 2018 Jul; 10(9). PMID: 30012580
Senescent cells accumulate in multiple aging-associated diseases, and eliminating these cells has recently emerged as a promising therapeutic approach. Here, we take advantage of the high lysosomal β-galactosidase activity of...